celecoxib has been researched along with Musculoskeletal Pain in 3 studies
Musculoskeletal Pain: Discomfort stemming from muscles, LIGAMENTS, tendons, and bones.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Other outcome measures included adverse events (AEs), laboratory tests, vital signs, electrocardiograms, and physical examinations." | 2.84 | A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis. ( Bin, SI; Cho, S; Choi, CH; Han, SB; In, Y; Kang, SB; Kim, J; Kim, JG; Kim, YM; Kyung, HS; Lee, BK; Lee, M; Moon, YW; Yoo, J, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, M | 1 |
| Yoo, J | 1 |
| Kim, JG | 1 |
| Kyung, HS | 1 |
| Bin, SI | 1 |
| Kang, SB | 1 |
| Choi, CH | 2 |
| Moon, YW | 1 |
| Kim, YM | 1 |
| Han, SB | 1 |
| In, Y | 1 |
| Kim, J | 1 |
| Lee, BK | 1 |
| Cho, S | 1 |
| Park, SM | 1 |
| Baek, JH | 1 |
| Ko, YB | 1 |
| Lee, HJ | 1 |
| Park, KJ | 1 |
| Ha, YC | 1 |
| Hochberg, MC | 1 |
| Martel-Pelletier, J | 1 |
| Monfort, J | 1 |
| Möller, I | 1 |
| Castillo, JR | 1 |
| Arden, N | 1 |
| Berenbaum, F | 1 |
| Blanco, FJ | 1 |
| Conaghan, PG | 1 |
| Doménech, G | 1 |
| Henrotin, Y | 1 |
| Pap, T | 1 |
| Richette, P | 1 |
| Sawitzke, A | 1 |
| du Souich, P | 1 |
| Pelletier, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Non-Inferiority Clinical Trial On The Efficacy And Safety Of Chondroitin Sulfate And Glucosamine Hydrochloride In Combination Versus Celecoxib In Patients With Knee Osteoarthritis[NCT01425853] | Phase 4 | 606 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Use of rescue medication as number of paracetamol tablets 500 mg since the last visit. The tablet count was reconciled with the patient diary.~Total Number of pills per month" (NCT01425853)
Timeframe: 6 months
| Intervention | daily tablets consumed/month (Mean) |
|---|---|
| Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican) | 31.0 |
| Celecoxib | 29.0 |
The safety evaluation was done in the set of randomized patients who took at least one dose of the medication (NCT01425853)
Timeframe: 6 months
| Intervention | number of participants (Number) |
|---|---|
| Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican) | 155 |
| Celecoxib | 151 |
"The OARSI Standing Committee for Clinical Trials Response Criteria Initiative and the OMERACT committee, in concert with the international rheumatology community, has led to the development of a uniform core set of outcome measures for OA. One of the objectives was to propose a set of criteria for measurement based on multiple domains to present the results of changes after treatment in symptomatic parameters as a single variable for clinical trials.~To be considered as responder patients should met one the following criteria:~High improvement in pain or in function ≥ 50% and absolute change ≥ 20 or~Improvement in at least 2 of the 3 following:~Pain ≥ 20% and absolute change ≥ 10~Function ≥ 20% and absolute change ≥ 10~Patient's global assessment ≥ 20% and absolute change ≥ 10" (NCT01425853)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican) | 79.7 |
| Celecoxib | 79.2 |
Study knees were evaluated at each visit for the presence or absence of swelling and/or effusion. (NCT01425853)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican) | 4.1 |
| Celecoxib | 3.8 |
Study knees were evaluated at each visit for the presence or absence of swelling and/or effusion. (NCT01425853)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican) | 5.9 |
| Celecoxib | 4.5 |
Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC) Pain subscale Score Range: 0 (no pain) - 500 (maximum pain) The study was designed such that the outcome of primary interest is knee pain related to OA. The measure selected to best evaluate this is an improvement in the WOMAC pain subscales. This subscale consists of 5 items which assesses the pain during walking, using stairs, in bed, sitting or lying, and standing. (NCT01425853)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican) | 185.79 |
| Celecoxib | 184.67 |
"EuroQoL-5D was a standardized instrument for use as a measure of health outcome that provides a simple descriptive profile and a single index value for health status. It was assessed at all of the study visits.~The EQ-5D-3L essentially consists of 2 pages - the EQ-5D descriptive system (page 2) and the EQ visual analogue scale (EQ VAS) (page 3). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. Total scale range for each dimension reported is 1 to 3.~The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. This information can be used as a quantitative measure of health outcome as judged by the individual respondents.~Total scale range for VAS dimension reported is 0 to 100." (NCT01425853)
Timeframe: 6 months
| Intervention | points (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mobility Baseline | Mobility 180 Days | Self-care Baseline | Self-care 180 days | Usual activities Baseline | Usual activities 180 days | Pain Discomfort Baseline | Pain Discomfort 180 days | Anxiety depression baseline | Anxiety depression 180 days | VAS Baseline | VAS 180 days | |
| Celecoxib | 1.84 | 1.46 | 1.44 | 1.21 | 1.79 | 1.42 | 2.27 | 1.86 | 1.60 | 1.34 | 52.488 | 70.219 |
| Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican) | 1.84 | 1.52 | 1.39 | 1.19 | 1.78 | 1.42 | 2.25 | 1.84 | 1.70 | 1.43 | 54.545 | 69.080 |
"Visual Analogue Scale: 0 No Pain 100 Maximum Pain Huskisson's VAS measures global pain intensity. Patients were asked to quantify their disease status on a 100 mm VAS as follows: Please indicate the severity of knee pain experienced during the last 48 hours by marking a (I) through the line. Left hand marker represents No pain and right hand marker represents The worst pain imaginable." (NCT01425853)
Timeframe: 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 180 days | |
| Celecoxib | 73.47 | 37.64 |
| Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican) | 72.79 | 37.86 |
The safety evaluation was done in the set of randomized patients who took at least one dose of the medication (NCT01425853)
Timeframe: 6 months
| Intervention | number of events (Number) | ||||
|---|---|---|---|---|---|
| Treatment-related AEs: Definitive | Treatment-related AEs: Possibly | Treatment-related AEs: Probably | Treatment-related AEs: Non-appraisable | Treatment-related AEs: unlikely or unrelated | |
| Celecoxib | 10 | 38 | 12 | 1 | 90 |
| Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican) | 3 | 43 | 25 | 0 | 84 |
"The investigator were asked to evaluated the patient's response to therapy of the index knee by marking a (I) a VAS scale with range 0 mm (best) and 100 mm (worst) as follows: Left hand marker Excellent-Best possible anticipated response, considering the severity and stage of the disease, right hand marker None-no response, absence of drug effect." (NCT01425853)
Timeframe: 6 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| PGA Therapy Baseline | PGA Therapy 180 days | IGA Therapy Baseline | IGA Therapy 180 days | |
| Celecoxib | 45.9 | 36.04 | 42.25 | 33.83 |
| Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican) | 54.59 | 36.85 | 51.4 | 34.72 |
"Patients were asked to quantify their disease status on a VAS scale with range 0 mm (best) and 100 mm (worst) as follows: Considering all the ways your arthritis of the knee affects you, mark (I) on the scale how well you are doing. Left hand marker Very Well, Right hand marked Very Poor." (NCT01425853)
Timeframe: 6 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| PGA Activity Baseline | PGA Activity 180 days | IGA Activity Baseline | IGA Activity 180 daus | |
| Celecoxib | 69.41 | 36.88 | 63.28 | 33.40 |
| Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican) | 69.11 | 38.35 | 63.2 | 35.33 |
Western Ontario & McMaster Universities Osteoarthritis Index, from 0 No Function to 1700 Maximum Function WOMAC functional limitation subscale was used to measure the functionality of the knee with pain. Seventeen items are used to assess functionality of the knee: tair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties. (NCT01425853)
Timeframe: 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 180 days | |
| Celecoxib | 1111.60 | 595.78 |
| Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican) | 1131.40 | 616.96 |
Western Ontario & McMaster Universities Osteoarthritis Index, from 0 No Stiffness to 200 Maximum Stiffness WOMAC stiffness subscale was used to measure the stiffness of the knee with pain. Two items are used to assess stiffness grade: after first waking and later in the day. (NCT01425853)
Timeframe: 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 180 days | |
| Celecoxib | 129.48 | 65.78 |
| Chondroitin Sulfate/ Glucosamine Hydrochloride (Droglican) | 130.15 | 69.06 |
2 trials available for celecoxib and Musculoskeletal Pain
| Article | Year |
|---|---|
A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; | 2017 |
Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib.
Topics: Aged; Celecoxib; Chondroitin Sulfates; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Combin | 2016 |
1 other study available for celecoxib and Musculoskeletal Pain
| Article | Year |
|---|---|
Management of acute calcific tendinitis around the hip joint.
Topics: Adult; Aged; Analgesics, Opioid; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Arthro | 2014 |